SPECIAL EMPHASIS PANELS
To view other meetings from ZAI1 choose calendar year:
| Study Section | Panel Name | Meeting Rosters |
|---|---|---|
| ZAI1 PT-I(S1) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 05/24/24 |
| ZAI1 RD-M(S1) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 05/21/24 |
| ZAI1 JTS-I(M3) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 05/13/24 |
| ZAI1 LK-A(C2) | HUMORAL IMMUNOLOGY CORE LABORATORY FOR AIDS VACCINE RESEARCH AND DEVELOPMENT (N01) | 05/09/24 |
| ZAI1 CAB-M(S1) | NIAID RESOURCE-RELATED RESEARCH PROJECTS (R24 CLINICAL TRIAL NOT ALLOWED) | 05/08/24 |
| ZAI1 SA-A(C2) | RESOURCE SUPPORT PROGRAM FOR AIDS VACCINE DEVELOPMENT (N01) | 05/06/24 |
| ZAI1 MMO-I(S1) | NIAID CLINICAL TRIAL PLANNING GRANTS (R34 CLINICAL TRIAL NOT ALLOWED) | 05/01/24 |
| ZAI1 MFH-M(S1) | NIAID CLINICAL TRIAL PLANNING GRANTS (R34); NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01); NIAID SBIR PHASE II CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U44); INVESTIGATOR INITIATED EXTENDED CLINICAL TRIAL (R01) | 04/30/24 |
| ZAI1 JTS-I(M2) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 04/29/24 |
| ZAI1 KSW-A(M1) | ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH COMMITTEE (AIDS) SPECIAL EMPHASIS PANEL | 04/19/24 |
| ZAI1 FDS-M(M1) | ADVANCING DEVELOPMENT OF DIAGNOSTICS FOR CONGENITAL AND ADULT ACQUIRED SYPHILIS (R21 CLINICAL TRIAL NOT ALLOWED) | 04/18/24 |
| ZAI1 VS-A(M1) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) AND INVESTIGATOR INITIATED EXTENDED CLINICAL TRIAL (R01 CLINICAL TRIAL REQUIRED) | 04/12/24 |
| ZAI1 AWA-M(S1) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 04/12/24 |
| ZAI1 AWA-M(S2) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 04/10/24 |
| ZAI1 MR-I(M2) | NIAID RESOURCE RELATED RESEARCH PROJECTS (R24 CLINICAL TRIAL NOT ALLOWED) | 04/03/24 |
| ZAI1 CAB-D(M1) | NIH SUPPORT FOR CONFERENCES AND SCIENTIFIC MEETINGS (PARENT R13 CLINICAL TRIAL NOT ALLOWED) | 03/26/24 |
| ZAI1 SPJ-D(M1) | SUPPORT FOR RESEARCH EXCELLENCE – FIRST INDEPENDENT RESEARCH (SURE-FIRST) AWARD (R16 - CLINICAL TRIAL NOT ALLOWED) | 03/21/24 |
| ZAI1 TCB-I(M2) | NIAID CLINICAL TRIAL PLANNING GRANTS (R34 CLINICAL TRIAL NOT ALLOWED) | 03/21/24 |
| ZAI1 RCU-A(M1) | ANALYZING EARLY EVENTS IN TB AND TB/HIV INFECTION FOR INTERVENTIONAL TARGETS (R01 CLINICAL TRIAL NOT ALLOWED) | 03/21/24 |
| ZAI1 PP-A(C2) | VIROLOGY CORE LABORATORY (VCL) | 03/20/24 |
| ZAI1 LG-M(M1) | FUNDAMENTAL RESEARCH TO UNDERSTAND THE MECHANISMS OF NEUROTROPIC VIRUS-MEDIATED DISEASE (R01 CLINICAL TRIAL NOT ALLOWED) | 03/20/24 |
| ZAI1 JTS-I(M1) | ALLERGY, IMMUNOLOGY, AND TRANSPLANTATION RESEARCH COMMITTEE (AITC) SPECIAL EMPHASIS PANEL | 03/18/24 |
| ZAI1 TCB-I(M1) | NIAID CLINICAL TRIAL PLANNING GRANTS (R34 CLINICAL TRIAL NOT ALLOWED) AND INVESTIGATOR INITIATED EXTENDED CLINICAL TRIAL (R01 CLINICAL TRIAL REQUIRED) | 03/14/24 |
| ZAI1 VSR-D(M1) | NIAID NEW INNOVATORS AWARDS (DP2 CLINICAL TRIAL NOT ALLOWED) | 03/11/24 |
| ZAI1 MR-I(M1) | SEX DIFFERENCES IN RADIATION RESEARCH: MODELS, UNDERLYING PATHWAYS, BIOMARKERS OF INJURY, AND MEDICAL COUNTERMEASURE RESPONSES (U01 CLINICAL TRIAL NOT ALLOWED) | 03/11/24 |
| ZAI1 BJM-A(M1) | NIAID RESOURCE RELATED RESEARCH PROJECTS (R24 CLINICAL TRIAL NOT ALLOWED) | 03/11/24 |
| ZAI1 LP-I(M1) | INVESTIGATOR INITIATED EXTENDED CLINICAL TRIAL (R01 CLINICAL TRIAL REQUIRED) | 03/08/24 |
| ZAI1 PT-I(M2) | NIAID SBIR PHASE II CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U44 CLINICAL TRIAL REQUIRED) | 03/07/24 |
| ZAI1 SB-X(M1) | DEVELOPMENT OF SOFTWARE FOR DATA SCIENCE IN INFECTIOUS AND IMMUNE-MEDIATED DISEASES RESEARCH (U01 CLINICAL TRIAL NOT ALLOWED) | 03/06/24 |
| ZAI1 SAS-M(M2) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED); INVESTIGATOR INITIATED EXTENDED CLINICAL TRIAL (R01 CLINICAL TRIAL REQUIRED) | 03/06/24 |
| ZAI1 AWA-M(M2) | NIAID SBIR PHASE II CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U44 CLINICAL TRIAL REQUIRED), CLINICAL TRIAL PLANNING GRANT (R34 CLINICAL TRIAL NOT ALLOWED), CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL | 03/06/24 |
| ZAI1 SA-A(C1) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: DEVELOPMENT OF LONG-ACTING TREATMENTS FOR HCV CURE (TOPIC 125) | 03/01/24 |
| ZAI1 SAS-M(M1) | NIAID SBIR PHASE II CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U44 CLINICAL TRIAL REQUIRED); NIAID CLINICAL TRIAL PLANNING GRANTS (R34 CLINICAL TRIAL NOT ALLOWED); NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT | 02/29/24 |
| ZAI1 MR-I(M3) | PAR-23-065, NIAID RESOURCE RELATED RESEARCH PROJECTS (R24 CLINICAL TRIAL NOT ALLOWED) | 02/29/24 |
| ZAI1 DF-M(M1) | ANIMAL MODELS FOR HEPATITIS B AND C (R01 CLINICAL TRIAL NOT ALLOWED) | 02/29/24 |
| ZAI1 AWA-M(M1) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED); NIAID SBIR PHASE II CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U44 CLINICAL TRIAL REQUIRED); CLINICAL TRIAL PLANNING GRANTS (R34 CLINICAL TRI | 02/29/24 |
| ZAI1 HSC-X(M1) | IMMUNE MECHANISMS AT THE MATERNAL-FETAL INTERFACE (R01 CLINICAL TRIAL NOT ALLOWED) | 02/28/24 |
| ZAI1 BJM-A(C1) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: DEVELOPMENT OF NOVEL IN-VITRO AND IN-VIVO MODELS TO SUPPORT NEUROHIV RESEARCH (TOPIC 002) | 02/27/24 |
| ZAI1 NKD-M(C2) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: SOFTWARE OR WEB SERVICES TO RE-REPRESENT EXISTING SCIENTIFIC DATA AND KNOWLEDGE INTO A KNOWLEDGE GRAPH FORMAT (TOPIC 136) | 02/27/24 |
| ZAI1 PT-I(M1) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 02/27/24 |
| ZAI1 SPJ-A(C2) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: POINT-OF-CARE HIV VIRAL LOAD AND DRUG ADHERENCE ASSAYS (TOPIC 001) | 02/26/24 |
| ZAI1 PT-I(C1) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I AND PHASE II: REAGENTS FOR IMMUNOLOGIC ANALYSIS OF NON-MAMMALIAN AND UNDERREPRESENTED MAMMALIAN MODELS (TOPIC 129) | 02/26/24 |
| ZAI1 JTS-I(C1) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I AND PHASE II: ADJUVANT DISCOVERY AND DOWN-SELECTION FOR VACCINES AGAINST INFECTIOUS AND IMMUNE-MEDIATED DISEASES (TOPIC 130) | 02/23/24 |
| ZAI1 PP-A(C1) | HHS-NIH-SBIR PHS 2024-1 PHASE I/II: DEVELOPMENT OF NEXT-GEN DEVICES AND MATERIALS-BASED PLATFORMS FOR THE ADMIN OF HIV-1 BNABS (TOPIC 124); PHS 2020-1 PHASE II: PARTICLE-BASED CO-DELIVERY OF HIV IMMUNOGENS AS NEXT-GEN VACCINES (TOPIC 77) | 02/22/24 |
| ZAI1 LK-A(C1) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: RAPID DIAGNOSTIC ASSAYS FOR SELF-MONITORING OF ACUTE OR REBOUND HIV-1 INFECTION (TOPIC 126) | 02/22/24 |
| ZAI1 SPJ-A(C1) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: SOFTWARE OR WEB SERVICES TO AUTOMATE METADATA ENRICHMENT AND STANDARDIZATION FOR DATA ON INFECTIOUS AND IMMUNE – MEDIATED DISEASES (TOPIC 135) | 02/21/24 |
| ZAI1 SJ-M(C2) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: DEVELOPMENT OF BACTERIOPHAGE FOR TREATMENT OF MYCOBACTERIAL INFECTIONS (TOPIC 131) | 02/21/24 |
| ZAI1 MN-M(C1) | SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROGRAM CONTRACT SOLICITATION (PHS 2022-1) TOPIC 108 - DEVELOPMENT OF RAPID POC DIAGNOSTICS FOR TREPONEMA PALLIDUM (N01) | 02/16/24 |
| ZAI1 MN-M(C2) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: NOVEL DIAGNOSTIC BIOMARKER DISCOVERY AND VALIDATION FOR MALARIA AND SELECT NEGLECTED TROPICAL DISEASES (NTDS) (TOPIC 132) | 02/15/24 |
| ZAI1 SAG-A(C1) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I/II: MULTIPLEXED PATIENT ADMINISTERED DIAGNOSTICS FOR HEPATITIS B, HEPATITIS C, AND HIV (TOPIC 127) | 02/15/24 |
| ZAI1 SJ-M(C1) | SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROGRAM CONTRACT SOLICITATION (PHS 2022-1) TOPIC 112 - DIGITAL TOOLS AGAINST MISINFORMATION ABOUT INFECTIOUS DISEASE TREATMENTS AND VACCINES (N01) | 02/14/24 |
| ZAI1 KAR-M(C2) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: ALTERNATIVES TO BENZATHINE PENICILLIN FOR TREATMENT OF SYPHILIS (TOPIC 134) | 02/12/24 |
| ZAI1 MMO-I(C1) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: ADJUVANT DEVELOPMENT FOR VACCINES FOR INFECTIOUS AND IMMUNE-MEDIATED DISEASES (TOPIC 128) | 02/08/24 |
| ZAI1 KJK-I(C1) | NIAID SPF MACAQUE BREEDING COLONIES | 02/07/24 |
| ZAI1 KAR-M(C1) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: DEVELOPMENT OF A SEROLOGICAL TEST FOR HERPES SIMPLEX TYPES 1 AND 2 INFECTIONS (TOPIC 133) | 02/06/24 |
| ZAI1 NKD-M(C1) | SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROGRAM CONTRACT SOLICITATION (PHS 2022-1) TOPIC 109 - DEVELOPMENT OF MONOCLONAL ANTIBODY-MEDIATED INTERVENTIONS TO COMBAT MALARIA (N01) | 02/06/24 |
| ZAI1 RK-M(M1) | BIOINFORMATICS RESOURCE CENTERS (BRCS) FOR INFECTIOUS DISEASES (U24 CLINICAL TRIAL NOT ALLOWED) | 01/31/24 |
| ZAI1 RCU-A(J1) | PA20-186, MIDCAREER INVESTIGATOR AWARD IN PATIENT-ORIENTED RESEARCH (PARENT K24 INDEPENDENT CLINICAL TRIAL NOT ALLOWED) | 01/24/24 |
| ZAI1 LP-I(C1) | INNOVATIONS IN FUNCTIONAL B CELL EPITOPE DISCOVERY (N01) | 01/18/24 |
| ZAI1 SA-A(J2) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 01/09/24 |